Armata Pharmaceuticals
ARMP
29 hedge funds and large institutions have $1.4M invested in Armata Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
29% more capital invested
Capital invested by funds: $1.08M → $1.4M (+$314K)
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
12% more funds holding
Funds holding: 26 → 29 (+3)
0.02% less ownership
Funds ownership: 2.05% → 2.03% (-0.02%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GWM
GSB Wealth Management
Guilford,
Connecticut
|
+$48.6K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$21.2K |
| 3 |
BlackRock
New York
|
+$4.43K |
| 4 |
Carson Wealth (CWM LLC)
Omaha,
Nebraska
|
+$1.62K |
| 5 |
Raymond James Financial
St Petersburg,
Florida
|
+$1.62K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$40.4K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$30.1K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$2.91K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.86K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$2.83K |
ARMP Hedge Fund Activity: Q2 2025 in Review
29 of the 7,612 institutional investors tracked by Wall St. Rank reported a position in Armata Pharmaceuticals (ARMP) for Q2 2025, worth a combined $1.4M — up 29% from $1.08M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ARMP positions and 2 closed out — a net gain of 3 holders — while 5 added to existing stakes and 4 trimmed.
The largest buyer was GSB Wealth Management, opening a new position worth an estimated $48.6K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $40.4K sold.
- 29 institutional investors held Armata Pharmaceuticals (ARMP) as of Q2 2025, up from 26 in Q1 2025.
- Funds reported $1.4M of Armata Pharmaceuticals stock for Q2 2025, up 29% quarter-over-quarter.
- 5 funds opened new Armata Pharmaceuticals positions in Q2 2025 and 2 closed out, a net change of +3 holders.
- The largest Armata Pharmaceuticals buyer in Q2 2025 was GSB Wealth Management, an estimated $48.6K added.
- The largest Armata Pharmaceuticals seller in Q2 2025 was Susquehanna International Group, an estimated $40.4K sold.
Based on aggregated 13F filings for Q2 2025.